Clinical trial
Evaluation of Effectiveness of Two Different Doses of Mivacurium in Modified Rapid Sequence Intubation for Emergency Surgery ,Prospective Randomized Double Blind Study
Name
mivacurium in RSI
Description
Mivacurium can be considered as an optimal choice for muscle relaxation in short duration surgeries, as butyrylcholinesterase can rapidly and reliably degrade this benzylisoquinoline muscle relaxant in vivo. However the histamine release related to a rapid high-dose injection, unsatisfactory intubation conditions and unexpected delay in recovery in patients may be encountered with butyrylcholinesterase deficiency
Trial arms
Trial start
2023-09-01
Estimated PCD
2024-01-01
Trial end
2024-01-01
Status
Recruiting
Treatment
"Mivacurium Chloride"
emergence modified sequence intubation
Arms:
Miva 3, Miva 4
Other names:
"Mivacron®"
Size
100
Primary endpoint
Intubation conditions during RSI.
3 months
Eligibility criteria
Inclusion Criteria:
* 20-60 year old patients.
* American society of anaesthesia (ASA) 1 and 2.
* Emergency surgery.
Exclusion Criteria:
* Refusal.
* allergy.
* neuromuscular disease.
* Suspected desaturation.
* Severe cardiac disease.
* Severe pulmonary disease.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'prospective randomized double blind', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'double blind', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-01-30
1 organization
Organization
Al-Azhar University